Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S, Hertogs K.
Goethals O, et al. Among authors: jochmans d.
J Virol. 2008 Nov;82(21):10366-74. doi: 10.1128/JVI.00470-08. Epub 2008 Aug 20.
J Virol. 2008.
PMID: 18715920
Free PMC article.